Press Releases

02.04.2022

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

02.01.2022

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA

02.01.2022

Pfizer Announces New Chief Development Officer

02.01.2022

Pfizer Invites Public to View and Listen to a Webcast with Pfizer Director Joseph Echevarria to Discuss Board Oversight of ESG

01.31.2022

Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program

01.28.2022

European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer

01.27.2022

Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment

01.25.2022

Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

01.24.2022

Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant

01.21.2022

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

01.18.2022

Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant

01.14.2022

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis